Status:
COMPLETED
Pharmacokinetics Of Alprazolam Sublingual Tablet Versus Conventional Tablet
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Anxiety Disorder
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
To assess if the sublingual tablet will have similar pharmacokinetics as the conventional tablet of alprazolam.
Eligibility Criteria
Inclusion
- Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2.
- Signed informed consent.
Exclusion
- Evidence or history of clinically significant abnormalities
- Positive drug screen, excessive alcohol and tobacco use
Key Trial Info
Start Date :
January 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT01256151
Start Date
January 1 2011
End Date
May 1 2011
Last Update
January 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511